Recombinant anti-tumor RNAse

Details Recombinant anti-tumor RNAse Recombinant anti-tumor RNAse

2007-03-13

2007-03-13

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C424S134100, C435S199000

Reexamination Certificate

active

09948391

ABSTRACT:
This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.

REFERENCES:
patent: 5840840 (1998-11-01), Rybak et al.
patent: 6395276 (2002-05-01), Rybak et al.
patent: WO 97/31116 (1997-08-01), None
patent: WO 97/31116 (1997-08-01), None
patent: WO 97/38112 (1997-10-01), None
patent: WO 98/50435 (1998-11-01), None
patent: WO 99/50398 (1999-10-01), None
Ardelt et al (1991, J. Biol. Chem. vol. 266, pp. 245-251), IDS 7.
Newton et al (1998, Biochemistry vol. 37, pp. 5173-5183), IDS 17.
Newton et al (1997, Protein Engineering, vol. 10, pp. 463-470), IDS 16.
Chen et al (Nucleic Acids Res. Jun. 15, 2000: 28(12): 2375-82).
Ardelt, W. et al. “Amino Acid Sequence of an Anti-Tumor Protein fromRana pipiensOocytes and Early Embryos/ Homology to Pancreatic Ribonucleases,”J. Biol. Chem. 1991, pp. 245-251, vol. 266, No. 1.
Boix, E. et al. “Role of the N-Terminus in RNase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity,”J. Mol. Biol. 1996, pp. 992-1007, vol. 257.
Inokuchi et al. “Primary Structures of Base Non-Specific and Acid Ribonuclease from Bullfrog (Rana catesbeiana)”Biol. Pharm. Bull1997, pp. 471-478, vol. 20, No. 5.
Kobe et al. “A structural Basis of the Interactions Between Leucine-Rich Repeats and Protein Ligands,”Nature1995, pp. 183-186, vol. 374.
Leung, S.O. et al. “Recombinant Expression of Ribonuclease ofRana pipienOrigin,”Proceedings of the 90thAnnual Meeting of The American Association for Cancer Research, Philadelphia, PA, Apr. 10-14, 1999, pp. 353-354, vol. 40 (Abstract #2341).
Liao et al. “Large-Scale Preparation of a Ribonuclease fromRana catesbeiana(Bullfrog) Oocytes and Characterization of its Specific Cytotoxic Activity Against Tumor Cells”Protein Expression and Purfication1996, pp. 194-202, vol. 7.
Mansfield et al. “Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors”BloodSep. 1997, pp. 2020-2026, vol. 90, No. 5.
Mansfield et al. “Recombinant RFB4 Single-Chain Immunotoxin that is Cytotoxic Towards CD22-Positive Cells”Biochem. Soc. Trans. 1997, pp. 709-714, vol. 25.
Mosimann, S.C. et al. “Refined 1-7 Å X-Ray Crystallographic Structure of P-30 Protein, an Amphibian Ribonuclease with Anti-Tumor Activity,”J. Mol. Biol. 1994, pp. 1141-1153, vol. 236.
Newton, D.L. et al. “Expression and Characterization of a Cytotoxic Human-Frog Chimeric Ribonuclease: Potential for Cancer Therapy,”Protein Engineering1997, pp. 463-470, vol. 10, No. 4.
Newton, D.L. et al. “Single Amino Acid Substitutions at the N-Terminus of a Recombinant Cytotoxic Ribonuclease Markedly Influence Biochemical and Biological Properties,”Biochemistry1998, pp. 5173-5183, vol. 37, No. 15.
Newton, D.L. et al. “Angiogenin Single-Chain Immunofusions: Influence of Peptide Linkers and Spacers Between Fusion Protein Domains”Biochemistry1996, pp. 545-553, vol. 35.
Newton, D.L. et al. “Anti-Tumor Ribonuclease, Combined with or Conjugated to Monoclonal Antibody MRK16, Overcomes Multidrug Resistance to VincristineIn VitroandIn Vivo” Int'l. Oncology1996, pp. 1095-1104, vol. 8.
Rybak et al. “Cytoxic Onconase and Ribonuclease A Chimeras: Comparison andin VitroCharacterization”Drug Delivery1993, pp. 3-10, vol. 1.

Affiliated with

Also associated with

Rating

Recombinant anti-tumor RNAse does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant anti-tumor RNAse, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-tumor RNAse will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3748443